疫苗经历年轻成人如何?PCV21在19-64岁有基础疾病的疫苗经历美国成人中的成本效果
本研究评估21价肺炎球菌结合疫苗(PCV21)对比推荐替代方案(PPSV23、PCV15、PCV20)在19-64岁有基础疾病且既往接种过肺炎球菌疫苗的美国成人中的成本效果。采用已发表的静态多队列状态转移马尔可夫模型,估算终身增量临床和社会经济结局。结果显示,在多数情景下PCV21具有成本效果或成本节约。
要点
- 在19-49岁既往接种PCV13或PCV15者中,PCV21对比PPSV23的增量成本效果比分别为每获得一个质量调整生命年99,700美元和149,300美元。
- 在50-64岁既往接种PCV13或PCV15者中,PCV21对比PPSV23的增量成本效果比分别为每获得一个质量调整生命年62,400美元和85,400美元。
- PCV21在多个疫苗经历人群中对比PCV15或PCV20具有成本节约。
核心结论
- 在19-64岁有基础疾病的美国成人中,使用PCV21在广泛情景下多数情况具有成本效果或成本节约。
研究设计与样本
- 采用已发表的静态多队列状态转移马尔可夫模型,估算单剂PCV21在19-64岁既往接种过PPSV23或PCV13(5年前)或PCV15(2年前)成人中的终身增量临床和社会经济结局。
- 成本和总质量调整生命年按每年3%贴现(2023年美元),报告增量成本效果比(每获得一个质量调整生命年所需美元)。
- 进行了概率敏感性分析、确定性敏感性分析和情景分析。
主要发现
- 在19-49岁人群中,对比PPSV23,既往接种PCV13者使用PCV21的增量成本效果比为99,700美元/质量调整生命年,既往接种PCV15者为149,300美元/质量调整生命年。
- 在19-49岁人群中,PCV21对比PCV15在既往接种PPSV23者中具有成本节约,对比PCV20在所有疫苗经历人群中具有成本节约。
- 在50-64岁人群中,对比PPSV23,既往接种PCV13者使用PCV21的增量成本效果比为62,400美元/质量调整生命年,既往接种PCV15者为85,400美元/质量调整生命年。
- 在50-64岁人群中,PCV21对比PCV15或PCV20在所有疫苗经历人群中具有成本节约。
- 确定性敏感性分析识别贴现率和疫苗效果为最具影响力的输入;概率敏感性分析确认结果的稳健性;情景分析显示将既往接种PPSV23或PCV13的年轻成人末次接种时间延长至8年时增量成本效果比仅有微小变化。
关键数值与推荐
- 19-49岁既往接种PCV13者:PCV21对比PPSV23的增量成本效果比为99,700美元/质量调整生命年。
- 19-49岁既往接种PCV15者:PCV21对比PPSV23的增量成本效果比为149,300美元/质量调整生命年。
- 50-64岁既往接种PCV13者:PCV21对比PPSV23的增量成本效果比为62,400美元/质量调整生命年。
- 50-64岁既往接种PCV15者:PCV21对比PPSV23的增量成本效果比为85,400美元/质量调整生命年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Because of the residual pneumococcal disease burden among vaccine-experienced adults aged 19-64 years with underlying medical conditions in the U.S., the Advisory Committee on Immunization Practices recommended revaccination with higher valent pneumococcal conjugate vaccine. After the introduction of the 21-valent pneumococcal conjugate vaccine (PCV21) in 2024, it was added as an option. This study evaluated the cost-effectiveness of PCV21 versus the recommended alternatives (23-valent pneumococcal polysaccharide vaccine [PPSV23], 15-valent pneumococcal conjugate vaccine [PCV15], and 20-valent pneumococcal conjugate vaccine [PCV20]) in this population. METHODS: A published static multicohort state-transition Markov model was used to estimate the lifetime incremental clinical and societal economic outcomes of administering a single dose of PCV21 in adults aged 19-64 years who were previously vaccinated 5 years ago with PPSV23 or PCV13 or 2 years ago with PCV15. The estimated total quality-adjusted life years and costs (in 2023 U.S. dollars) were discounted at an annual rate of 3% as well as the incremental cost-effectiveness ratios reported as $ per quality-adjusted life years gained. Probabilistic and deterministic sensitivity analyses and scenario analysis were conducted. RESULTS: Among those aged 19-49 years, compared with PPSV23, the incremental cost-effectiveness ratio of PCV21 PCV13- and PCV15--experienced adults was $99,700 and $149,300, respectively. PCV21 was cost-saving compared with PCV15 in the PPSV23-experienced and compared with PCV20 across all vaccine-experienced population. Among those aged 50-64 years, compared with PPSV23, the incremental cost-effectiveness ratio of PCV21 was $62,400 per quality-adjusted life years in PCV13-experienced and $85,400 in PCV15-experienced. PCV21 was cost-saving compared with PCV15 or with PCV20 across all vaccine-experienced population. The deterministic sensitivity analysis identified that discount rates and vaccine effectiveness were the most influential inputs. The probabilistic sensitivity analysis confirmed the results' robustness. The scenario analysis showed only minor changes in incremental cost-effectiveness ratio when the time since last vaccination was extended to 8 years for the PPSV23 or PCV13-experienced younger adults. CONCLUSIONS: The use of PCV21 in U.S. adults aged 19-64 years with underlying medical conditions can be cost-effective or cost-saving in most cases across a wide range of scenarios.
引用
- Yi Z, Elbasha EH, Owusu-Edusei K, et al. What About Vaccine-Experienced Younger Adults? Cost-Effectiveness of PCV21 Use in Vaccine-Experienced US Adults Aged 19-64 Years with Underlying Medical Conditions. Am J Prev Med. 2025. PMID: 41110559. doi:10.1016/j.amepre.2025.108159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。